GlassScriptPhysician profile
Isabel Marcano Bonilla
NPI 1902293863
$1,056.97
in general payments reported to CMS, 2019-2025
17 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.66 · 2021: $367 · 2022: $164 · 2023: $214 · 2024: $26.58 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $226.23 | 2021-2023 | Dexcom G6 Transmitter |
| Acerus Pharmaceuticals Corporation | $141.46 | 2021 | |
| Amgen INC. | $115.50 | 2023-2025 | Evenity |
| Medtronic, INC. | $98.43 | 2025 | Kyphon Express II Kyphopak Tray |
| Sanofi-Aventis U.S. LLC | $76.15 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $64.96 | 2021-2023 | Recorlev |
| Lilly USA, LLC | $63.28 | 2020-2022 | |
| Corcept Therapeutics | $47.93 | 2022-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.87 | 2020-2023 | Jardiance |
| Radius Health, INC. | $29.42 | 2022 | |
| Novo Nordisk INC | $27.96 | 2020 | |
| Recordati_rare_diseases_inc. | $23.67 | 2023 | Isturisa, Signifor Lar |
| Esperion Therapeutics, INC. | $21.20 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.05 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.23 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $20.00 | 2023 | Cequr Simplicity |
| Lifescan, INC. | $17.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Marcano Bonilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.